Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CAR-T-uning

Financiado

Cerrado

Chimeric Antigen Receptor (CAR) T Cell Therapy For Solid Tumors

CAR-T(uning) will assess the technical and commercial feasibility of an improved and broadly applicable chimeric antigen receptor T-cell (CAR-T) approach based on a novel implemented mechanism of action. There is an urgent need fo... ver más

29/02/2024

MUI

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

MEDIZINISCHE UNIVERSITAT INNSBRUCK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-29

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1 Objective:Objectives:

I+D

Cerrada hace 3 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

MUI

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Tumor-Treg-Targeting Training Network for the education of the next generation sc... 1M€ Cerrado

ATECT Advanced T cell Engineered for Cancer Therapy 8M€ Cerrado

BITCAT Blocking Inhibition of T cell Co stimulation for Anti tumour... 243K€ Cerrado

ImmunoChip Nano-assisted digitalizing of cancer phenotyping for immunot... 2M€ Cerrado

INCITE Immune Niches for Cancer ImmunoTherapy Enhancement 4M€ Cerrado

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

Duración del proyecto: 19 meses Fecha Inicio: 2022-07-08
Fecha Fin: 2024-02-29

Líder del proyecto

MEDIZINISCHE UNIVERSITAT INNSBRUCK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto CAR-T(uning) will assess the technical and commercial feasibility of an improved and broadly applicable chimeric antigen receptor T-cell (CAR-T) approach based on a novel implemented mechanism of action. There is an urgent need for more effective treatment strategies against cancer, which remains the leading cause of death worldwide. Immuno-oncology regimens such as, immune checkpoint blockade therapy (ICT) and CAR-T therapy emerged as powerful tools in cancer treatment, however, in the majority of patients these fail to achieve long-lasting therapy response. Further, they remain costly and applicable to a limited range of cancer types. Specifically, CAR-T therapy faces two unresolved challenges: 1) limited therapy persistence; 2) tumor-induced immunosuppression. Consequently, no CAR-T therapy against solid tumor cancers has reached the market. Prof. Gottfried Baier has uncovered that inhibition of orphan nuclear receptor NR2F6, a downstream target of T cell antigen receptor signaling intermediate PKCθ, overcomes these shortcomings in a two-fold manner: 1) increased therapy persistence to improve its long-lasting effects; 2) reduced immunosuppression at the tumor site to improve immune response. Within this ERC PoC, first we will technically validate this approach using in vivo mouse and ex vivo patient-derived tumor models. We will focus on NSCLC as first indication, as it is one of the most-difficult to treat solid cancers with high mortality rate and disease burden. Subsequently, commercial feasibility will be determined by verifying IP position and strategy, performing in-depth market and competitor analyses, and finally consolidating these into a business plan to establish the best path to commercialization. Successful commercialization of CAR-T(uning) would reduce the socioeconomic burden of NSCLC, extending and improving patient lives, and enable the development of long-lasting, (cost-)effective CAR-T therapies applicable to a greater range of cancer types.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores